Leerink Partnrs Forecasts Stronger Earnings for 908 Devices

908 Devices Inc. (NASDAQ:MASS) – Equities research analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for shares of 908 Devices in a research report issued on Tuesday, May 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.20) for the quarter, up from their prior estimate of ($0.21). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices’ FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.54) EPS.

908 Devices (NASDAQ:MASS) last announced its earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The business had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research note on Saturday, May 10th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, 908 Devices currently has an average rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Stock Up 4.6%

Shares of NASDAQ:MASS opened at $4.52 on Friday. 908 Devices has a 12-month low of $1.81 and a 12-month high of $7.27. The company has a market cap of $161.54 million, a P/E ratio of -2.55 and a beta of 0.26. The company’s fifty day moving average is $4.58 and its two-hundred day moving average is $3.26.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MASS. Two Sigma Advisers LP acquired a new stake in shares of 908 Devices during the 4th quarter worth about $30,000. CWM LLC grew its stake in shares of 908 Devices by 541.2% in the first quarter. CWM LLC now owns 6,963 shares of the company’s stock worth $31,000 after purchasing an additional 5,877 shares during the last quarter. Prudential Financial Inc. acquired a new stake in 908 Devices during the 4th quarter valued at approximately $34,000. Occudo Quantitative Strategies LP acquired a new position in shares of 908 Devices in the 4th quarter valued at about $36,000. Finally, Two Sigma Investments LP acquired a new stake in 908 Devices in the fourth quarter worth $42,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, Director Mark Spoto acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 14th. The stock was acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the transaction, the director now owns 62,971 shares of the company’s stock, valued at $270,145.59. This trade represents a 18.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.70% of the company’s stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.